Evan Caplan

Director at AirNexis Therapeutics.

Raised on AirNexis Therapeutics filings

$62M

of $200M offered across 1 Form D filing

Form D filings: 1
Teammates: 5
Last filing: Mar 9, 2026

Company

AirNexis Therapeutics

Biotech · Palo Alto, CA

Inhaled PDE3/4 inhibitor for COPD maintenance

Inhaled PDE3/4 inhibitor for COPD maintenance

Investors: 13
Founded: 2024
Still open: $138M

Investors: 13
Sector: Biotech
Founded: 2024
HQ: Palo Alto, CA

AirNexis Therapeutics filings

AirNexis Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Mar 9, 2026	Equity	$62M/ $200M	Form D

EquityFiled Mar 9, 2026Form D
$62M/ $200M

Works with

Also named on AirNexis Therapeutics filings

Maria FardisChief Executive Officer, Form D signerForm D signer James LiExecutive Officer, Director Jill CarrollDirector Anna ChenDirector Colin WalshDirector